In addition, this study suggests that there is an imbalance between TNFR1 and TNFR2 signalling in patients with MS from the earliest clinical events and that this can have an important prognostic meaning, announcing the appearance of new cortical lesions and a clinical worsening of the disease. Here, TNFRSF1B is linked to myeloid sarcoma.